Clorox Reports Q3 Sales Decline, EPS Drop, and Significant Debt Increase Leading to Equity Deficit
summarizeSummary
Clorox's latest 10-Q shows declining sales and EPS, a significant increase in debt, and a concerning shift to a stockholders' equity deficit, indicating financial pressure.
check_boxKey Events
-
Weak Financial Performance
Net sales for the nine months ended March 31, 2026, decreased by 7% to $4.77 billion, and diluted EPS fell by 10% to $3.47 compared to the prior year. Gross margin also declined by 200 basis points for the nine-month period.
-
Significant Debt Increase & Equity Deficit
Notes and loans payable surged to $1.59 billion as of March 31, 2026, from $4 million on June 30, 2025, primarily to finance the GOJO acquisition and Glad venture payment. This led to total Clorox stockholders' equity shifting from a $321 million surplus to a $67 million deficit.
-
GOJO Acquisition Completed
The previously announced acquisition of GOJO Industries for approximately $2.25 billion was completed on April 1, 2026, financed by new credit facilities and commercial paper.
-
ERP System Implementation Completed
The company completed the phased implementation of its new enterprise resource planning (ERP) system in the third quarter of fiscal year 2026, which had previously impacted shipments.
auto_awesomeAnalysis
The 10-Q reveals a challenging financial quarter for Clorox, marked by a 7% decline in net sales and a 10% drop in diluted EPS for the nine-month period. A key concern is the substantial increase in short-term debt to $1.59 billion, primarily to fund the GOJO acquisition and Glad venture payment, which has resulted in the company's total stockholders' equity turning into a deficit of $67 million. This balance sheet deterioration, coupled with declining gross margins and a cautious macroeconomic outlook, signals significant financial strain and aligns with recent news of lowered earnings forecasts. The stock is currently trading near its 52-week lows, amplifying the negative market reaction to these results.
At the time of this filing, CLX was trading at $90.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.7B. The 52-week trading range was $93.39 to $142.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.